Elfunat (ethylmethylhydroxypyridine succinate) solution for injections 50 mg/ml. 2 ml. №10

Description

Elfunat Composition

active substance: methylmethylhydroxypyridine succinate 1 ml methylmethylhydroxypyridine succinate 50 mg
Elfunat excipients: water for injection.

Elfunat Dosage form

Injection.

Basic physical and chemical properties:

transparent, colorless or slightly brownish solution.

Pharmacological group

Drugs affecting the nervous system ATX code N07X X.

Pharmacological properties

Pharmacodynamics.

Elfunate is an inhibitor of free radical processes, a membrane protector, has antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body’s resistance to the effects of various damaging factors, to acidic pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, alcohol and antipsychotic drugs (neuroleptics) intoxication).

The drug improves cerebral metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins (LDL). Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

The mechanism of action of the drug is due to its antioxidant and membrane-protective action. Wine inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Modulates the activity of membrane-bound enzymes (non-calcium phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, gamma-aminobutyric acid (GABA), acetylcholine), which enhances their ability to bind to ligand-functional neu- transmission. Elfunate increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energosynthetic functions of mitochondria, and stabilization of cell membranes.

Pharmacokinetics.

When administered, the drug is determined in blood plasma within 4:00 after administration. The time to reach the maximum concentration is 0.45-0.5 hours. The maximum concentration at doses of 400-500 mg is 3.5-4.0 μg / ml. Elfunate quickly passes from the bloodstream to the organs of the i tissue and is quickly excreted from the body. It is excreted from the body in the urine, mainly in glucuronoconjugation form and in small quantities – unchanged.

Indications

Acute disorders of cerebral circulation
traumatic brain injury, the consequences of traumatic brain injury
encephalopathy
cardiopsychoneurosis
mild cognitive impairment of atherosclerotic genesis
anxiety disorders in neurotic i neurosis-like states
acute myocardial infarction (from the first day), as part of complex therapy
primary open-angle glaucoma of various stages, as part of complex therapy
relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders
acute intoxication with antipsychotic drugs
acute purulent-inflammatory processes in the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Contraindications

Acute hepatic or renal failure, hypersensitivity to the drug, childhood, pregnancy, lactation.

Interaction with other medicinal products and other forms of interaction

Elfunat enhances the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa). Reduces the toxic effect of ethyl alcohol.